title: [The actual place of anti-angiogenesis in non-small cell lung cancer].
abstract: Since the early 90's, it seems that chemotherapy given alone in non-small cell lung cancer had reached a plateau. Many different pathways have been targeted, with or without chemotherapy, trying to improve the treatment efficacy. Angiogenesis plays an important role in the process of the tumour growth and in metastasis dissemination. Two main ways have been developed to block either directly the most important growth factor (vascular endothelial growth factor) using a humanized monoclonal antibody, or its receptors (using low-molecular-weight anti tyrosine kinases). Some of them are currently available in colorectal cancers or renal cell cancer. Many phase II or III trials have been published in non small cell lung cancer in the last years.
authors.affiliation: Département de pneumologie, Hôpital Lyautey, CHU de Strasbourg, France. bertrand.mennecier@chru-strasbourg.fr
authors.forename: B
authors.initials: B
authors.lastname: Mennecier
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D042461:Vascular Endothelial Growth Factor A